ChemotherapyFDA-approvedFirst-line
Gemcitabine
How it works
Gemcitabine is a nucleoside analog that interferes with DNA synthesis, causing cancer cells to die.
Cancer types
Efficacy
Studies show that gemcitabine can improve survival in patients with pancreatic cancer, with a median overall survival of approximately 5.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Gemcitabine and Nab-Paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Gemcitabine and Nab-paclitaxel with TheraBionic P1 for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Rosmarinic Acid Enhances Cancer Treatment in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| Evaluating Safety and Effectiveness of Misetionamide in Ovarian Cancer Treatment | Ovarian Cancer | phase-1 | — | Source → |
| Testing AMP945 with Nab-paclitaxel and Gemcitabine for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Gemcitabine-Modified MicroRNA May Help Fight Lung Cancer | Lung Cancer | lab-study | Gem-miR-129 is a potent inhibitor, with an IC in the low nanomolar range in NSCLC cell lines. | Source → |
| Pancreatic Cancer Trial Investigates New Combination Therapy | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a New Cancer Treatment with Elimusertib and Gemcitabine | Pancreatic Cancer | phase-1 | — | Source → |
| Pancreatic Cancer Treatment Trial: Surufatinib, Gemcitabine, and Nab-Paclitaxel | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a New Way to Deliver Cancer Treatment for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| β-Hydroxybutyrate May Help Treat Non-Small Cell Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Testing IBI343 in Combination with Other Treatments for Advanced Solid Tumors | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Aerosol Gemcitabine for Solid Tumors with Lung Metastases | Melanoma | phase-1 | — | Source → |
| Testing ONT01 with Gemcitabine and Nab-paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a New Device for Delivering Chemotherapy to Pancreatic Cancer Patients | Pancreatic Cancer | phase-1 | — | Source → |
| Gemcitabine and Cisplatin with or without Veliparib for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing ZN-c3 and Gemcitabine in Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| PDK4's Role in Pancreatic Cancer Resistance to Gemcitabine | Pancreatic Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for Unresectable Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Testing ADI-PEG 20 with Gemcitabine and Docetaxel for Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Fostamatinib with Chemotherapy in Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing Cemiplimab Plus Gemcitabine for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a New Combination of Chemotherapy Drugs for Advanced Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Understanding Pancreatic Cancer Treatment Response | Pancreatic Cancer | lab-study | — | Source → |
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Gemcitabine and WEE1 Inhibitor Trial for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Gemcitabine, Dasatinib, and Erlotinib in Treating Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing Chemotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | preclinical | — | Source → |
| New Compound Shows Promise in Treating Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining Camrelizumab with Gemcitabine and Paclitaxel in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The median overall survival was 14.0 months, and the median progression-free survival was 6.4 months. | Source → |
| Gene BHLHE41 May Help Pancreatic Cancer Cells Respond Better to Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| IGF2BP2 helps cancer cells resist treatment in pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| OTUB1 linked to gemcitabine resistance in pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| New Nanoparticle Platform for Targeted Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| REG3A linked to gemcitabine resistance in pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Combining medications to treat advanced breast and ovarian cancer | Ovarian Cancer | phase-1 | There were 3 major responses (1CR, 2PR) at DL1, and 1 CR at DL-1. | Source → |
| Gemcitabine Resistance in Pancreatic Cancer: A New Target for Treatment | Pancreatic Cancer | lab-study | — | Source → |
| New Nanoparticles Help Deliver Cancer Treatment to Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine and Flurbiprofen May Help Kill Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Gold Nanoclusters Help Deliver Cancer Drug More Effectively | Breast Cancer | lab-study | The resultant Gem-AuNCs-BSA showed enhanced delivery of drug and therapeutic effects for the treatment of breast cancer and lung cancer with better efficacy than free Gemcitabine. | Source → |
| α-Asarone May Help Overcome Gemcitabine Resistance in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Bacteria in Pancreatic Tumors May Affect Treatment Effectiveness | Pancreatic Cancer | observational | High intratumoral bacterial abundance impaired aGC efficacy (DFS 9.4 vs 19.1 months, p < 0.001; OS 19.4 vs 34.0 months, p < 0.001), which was mitigated by postoperative ABT application (DFS 7.9 vs 12.4 months, p < 0.001, OS 15.2 vs 29.6 months, p < 0.001). | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Linked to Protein TSPAN15 | Pancreatic Cancer | lab-study | Venetoclax, a targeted inhibitor of TSPAN15, exhibits synergistic efficacy when combined with gemcitabine for treating PDAC both in vitro and in vivo. | Source → |
| New Approach to Treating Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine May Help Overcome Resistance to Leukemia Treatment | Leukemia | lab-study | — | Source → |
| Gemcitabine Signature Predicts Response in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The Gem+ patients who received adjuvant gemcitabine had significantly better median disease-free survival (DFS) compared to the Gem- patients (NR until 72 months of follow-up vs 19.0 months); stratified hazard ratio [HR]: 0.19; 95% CI, 0.04-0.86; P = .032 | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| Knocking Down a Gene May Help Pancreatic Cancer Cells Respond to Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine-resistant pancreatic cancer cells may be weakened by targeting SLC5A3 | Pancreatic Cancer | lab-study | — | Source → |
| Researchers Identify Key Player in Pancreatic Cancer Resistance | Pancreatic Cancer | lab-study | — | Source → |
| Combining a new drug with gemcitabine may improve pancreatic cancer treatment | Pancreatic Cancer | lab-study | Inhibition of AHR activity caused synergistic effects with gemcitabine, increasing effectiveness by 30-41%. | Source → |
| Gemcitabine-Immunoglobulin Nanoparticles Target Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | The IC of Gemcitabine for Panc-1 cancer cells dropped seven-fold when encapsulated in GIgG NPs. | Source → |
| Gemcitabine-loaded nanoparticles show promise in treating pancreatic cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining Gemcitabine and AZD 1775 May Improve Treatment for Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combining CHK1 Inhibitor with Gemcitabine May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Long-Term Outcomes of Pancreatic Cancer Treatment | Pancreatic Cancer | phase-3 | The median overall survival was 31.6 months in patients given GemCap. | Source → |
| Combining Nadunolimab with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The median overall survival was 13.2 months, and the 1-year survival rate was 58%. | Source → |
| New Nano-Drug Delivery System Tested for Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| New Lab Model Helps Test Melanoma Treatments | Melanoma | lab-study | The results showed a significant impact on the co-culture distribution of cells, decreasing the population of cancerous cells after the administration of Gemcitabine. | Source → |
| Comparing Chemotherapy Options for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | — | Source → |
| Flurbiprofen May Enhance Gemcitabine Treatment for Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Pancreatic Cancer Models Show Resistance to Gemcitabine | Pancreatic Cancer | animal-study | — | Source → |
| Combining Gemcitabine and Erlotinib May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | meta-analysis | Gem-Erlo significantly improved disease control rate (DCR) [odds ratio (OR) =1.74; 95% confidence interval (CI): 1.03 to 2.92; P=0.04]. | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Combining Nimotuzumab and Gemcitabine May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | phase-2 | After treatment, PR ratio, SD ratio, ORR, and DCR in the study group were significantly higher than those in the control group, and PD ratio was significantly lower than that in the control group (P < 0.05) | Source → |
| Gemcitabine Chemotherapy May Increase Pancreatic Cancer Spread | Pancreatic Cancer | lab-study | — | Source → |
| New Delivery Method for Cancer Drug Shows Promise | Pancreatic Cancer | lab-study | The in vivo pharmacokinetics revealed approximately 4-fold higher bioavailability of GEM-NPs in comparison with free GEM. | Source → |
| Pancreatic Cancer Research Uncovers Complexity in Testing Treatments | Pancreatic Cancer | lab-study | — | Source → |
| Parthenolide May Help Treat Pancreatic Cancer Cells Resistant to Gemcitabine | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Linked to Mitochondrial Metabolism | Pancreatic Cancer | lab-study | — | Source → |
| Combining Interferon-Alpha and Gemcitabine May Help Treat Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Resistance Spreads in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| New Delivery Method for Pancreatic Cancer Treatment Shows Promise | Pancreatic Cancer | lab-study | LipotcGem inhibited tumor growth by 70% in subcutaneous xenograft model and 90% in orthotopic xenograft model, respectively. | Source → |
| Pancreatic Cancer Treatment Comparison in Morocco | Pancreatic Cancer | observational | The median overall survival was 6 months for patients treated with Folfirinox versus 3 months for those treated with Gemcitabine. | Source → |
| Combining two treatments may slow pancreatic cancer growth | Pancreatic Cancer | animal-study | Sel-GemPac enhanced the survival of treated mice compared to controls (p < .05). | Source → |
| Gemcitabine Affects Traditional Chinese Medicine Formula in Lung Cancer Treatment | Lung Cancer | animal-study | — | Source → |
| New Delivery Method for Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | LipodmGEM showed a greatly extended half-life (7.22 vs. 1.78 hours) compared to free GEM. | Source → |
| Gemcitabine Sensitivity Predicted in Pancreatic Cancer Patients | Pancreatic Cancer | phase-3 | GemPred+ patients who received adjuvant GEM had a median disease-free survival of 27.3 months (HR, 0.43 [95% CI, 0.29 to 0.65]; p < .001) and cancer-specific survival of 68.4 months (HR, 0.42 [95% CI, 0.27 to 0.66]; p < .001). | Source → |
| Gemcitabine and Trabectedin Combination Shows Promise in Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Resistance in Pancreatic Cancer: Understanding and Overcoming | Pancreatic Cancer | review | — | Source → |
| Gemcitabine Nanoparticles Show Promise in Treating Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Exosomes May Predict Chemotherapy Response in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Researchers Identify Gene Involved in Pancreatic Cancer Resistance to Treatment | Pancreatic Cancer | lab-study | — | Source → |
| New Cancer Treatment Combination Shows Promise in Pancreatic Cancer | Pancreatic Cancer | phase-1/2 | Among the 21 patients treated at the maximum tolerated dose, 6 (29%) experienced partial response, and median progression-free survival and overall survival times were 11.0 months and 16.2 months, respectively. | Source → |
| Marine-Derived Metabolite Enhances Effectiveness of Cancer Drug | Colorectal Cancer | lab-study | — | Source → |
| GAS5 Gene May Help Overcome Resistance to Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Combining Gemcitabine and Nab-Paclitaxel in Ovarian Cancer Treatment | Ovarian Cancer | observational | The median progression-free survival was 9 months (95% CI, 5.7-20.7). | Source → |
| Gemcitabine and Targeted Drugs in Pancreatic Cancer Treatment | Pancreatic Cancer | review | — | Source → |
| Gemcitabine Therapy for Pancreatic Cancer: A Computer Model Study | Pancreatic Cancer | lab-study | — | Source → |
| Gene Therapy to Overcome Pancreatic Cancer Resistance | Pancreatic Cancer | lab-study | — | Source → |
| Heat Therapy and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-3 | Median post-recurrence survival was significantly prolonged in the GPH-group (15.3 versus 9.8 months; p = 0.031). | Source → |
| Gemcitabine's Effectiveness in Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The adjusted difference in median overall survival was 3.2 months (95% CI, 1.1-7.4) for FOLFIRINOX compared to gemcitabine plus nab-paclitaxel. | Source → |
| Gemcitabine Prodrug Shows Promise in Overcoming Cancer Resistance | Pancreatic Cancer | lab-study | WRQ-2 exhibited high cytotoxicity against six cancer cell lines with IC values in the low micromolar range. | Source → |
| Arsenic Trioxide Sensitizes Pancreatic Cancer Cells to Gemcitabine | Pancreatic Cancer | lab-study | — | Source → |
| Combining Nardoguaianone L with Gemcitabine May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| New Insights into Pancreatic Cancer Treatment | Pancreatic Cancer | review | — | Source → |
| Combining Plant Extract and Gemcitabine May Help Treat Pancreatic Cancer | Pancreatic Cancer | animal-study | — | Source → |
| Link between Dicer enzyme and pancreatic cancer metabolism | Pancreatic Cancer | lab-study | — | Source → |
| Combining drugs to treat pancreatic cancer | Pancreatic Cancer | review | — | Source → |
| Gemcitabine plus nab-paclitaxel for elderly pancreatic cancer patients | Pancreatic Cancer | observational | The median overall survival was 10.8 months in the gemcitabine plus nab-paclitaxel group. | Source → |
| MicroRNA-497 May Help Overcome Pancreatic Cancer Resistance | Pancreatic Cancer | lab-study | — | Source → |
| Pancreatic Cancer Cells May Resist Treatment with Gemcitabine and TRAIL | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Linked to Energy Metabolism | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine and Nab-Paclitaxel Not Cost-Effective for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | Mean survival was lower for patients in the Gem-Nab than the FOLFIRINOX group (0.98 vs 1.26 life-years; incremental effectiveness = -0.28 life-years [95% confidence interval = -0.47 to -0.13]). | Source → |
| Gemcitabine Treatment May Be More Effective Against Pancreatic Cancer | Pancreatic Cancer | animal-study | EC-FAK loss reduced liver and lung metastasis load and improved survival rates in gemcitabine-treated mice. | Source → |
| Gemcitabine Chemotherapy May Be Enhanced by Calcium Channel Blockers in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| FOLFIRINOX as Second-Line Treatment for Pancreatic Cancer | Pancreatic Cancer | meta-analysis | FOLFIRINOX had a significantly longer progression-free survival (PFS) (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.52, 0.89) and overall survival (OS) (HR 0.71, 95% CI 0.59, 0.86); and a significantly better objective response rate (ORR) (HR 0.43, 95% CI 0.23, 0.80) and disease control rate (DCR) (HR 0.71, 95% CI 0.58, 0.88). | Source → |
| New Cancer Treatment Shows Promise for Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Combination Therapy for Esophageal Cancer Shows Promise | Leukemia | phase-3 | The total treatment efficiency in the study group was 86%. | Source → |
| Glucose Solution May Reduce Pain from Cancer Treatment | Pancreatic Cancer | observational | Glucose significantly decreased the frequency of GEM-induced vascular pain during the first GEM administration (36% vs. 55%, p=0.005). | Source → |
| Targeted Cancer Therapy Using Gemcitabine Conjugates | Lung Cancer | lab-study | — | Source → |
| Combining GW8510 and Gemcitabine May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Linked to a Specific Gene | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Linked to HAT1 | Pancreatic Cancer | lab-study | HAT1 depletion caused a notable increase of gemcitabine sensitivity in gemcitabine-resistant pancreatic cancer cell lines. | Source → |
| Testing Chemotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Gemcitabine Efficacy Enhanced by K73-03 in Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | — | Source → |
| Repurposing Existing Drugs to Improve Prostate Cancer Treatment | Prostate Cancer | lab-study | The radiation sensitizer enhancement ratio (SER) of menadione was 1.02 in normoxia and 1.15 in hypoxia, while the SER of gemcitabine was 1.27 in normoxia and 1.09 in hypoxia. | Source → |
| Combining Rose Bengal with Gemcitabine May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | animal-study | — | Source → |
| Gemcitabine and nab-paclitaxel in older patients with pancreatic cancer | Pancreatic Cancer | observational | Median progression-free survival was 5.5 months, and overall survival was 12.0 months in the older group. | Source → |
| Combining Cancer Treatment with Immune System Boosters | Colorectal Cancer | animal-study | The combined therapy prolonged median overall survival of Mlh1 mice from four weeks to 12 weeks. | Source → |
| Gold Nanoshells Help Deliver Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Pancreatic Cancer Recurrence Study Finds Factors Affecting Survival | Pancreatic Cancer | phase-3 | — | Source → |
| Combining Zebularine with Gemcitabine May Improve Cancer Treatment | Pancreatic Cancer | lab-study | Zebularine increased cellular gemcitabine concentration by 2-fold, and when co-delivered with liposomes, increased it by 4-fold. | Source → |
| Gemcitabine Sensitivity in Pancreatic Cancer Cells Improved by Restoring miRNA-217 Levels | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine Works Better Against Pancreatic Cancer When RAGE is Blocked | Pancreatic Cancer | animal-study | — | Source → |
| Comparing Treatments for Advanced Pancreatic Cancer | Pancreatic Cancer | observational | The median disease control rates were 82.6% for gemcitabine with nab-paclitaxel and 67.9% for modified FOLFIRINOX. | Source → |
| Combination Chemotherapy May Help Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The rate of progressive disease after three cycles of chemotherapy was reduced from 45.6% with gemcitabine to 25.4% with the combination of Nab-paclitaxel and gemcitabine. | Source → |
| Gemcitabine Resistance in Pancreatic Cancer Studied | Pancreatic Cancer | lab-study | — | Source → |
| New Approach to Overcome Gemcitabine Resistance in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| New Chemotherapy Combination Shows Promise for Ovarian Clear Cell Carcinoma | Ovarian Cancer | phase-1 | Two evaluable patients showed a partial response. | Source → |
| Targeted Cancer Treatment Using Ultrasound-Activated Liposomes | Ovarian Cancer | lab-study | Cellular uptake of GMC-SoS Fo LPs improved 6.51-fold over GMC LPs under ultrasonic irradiation. | Source → |
| Comparing Chemotherapy Options for Pancreatic Cancer | Pancreatic Cancer | review | FOLFIRINOX had significantly better overall survival (OS) and relapse-free survival (RFS)/disease-free survival (DFS)/progression-free survival (PFS) compared to gem-cap and gem-nab/P. | Source → |
| Combining Eribulin and Gemcitabine for Triple Negative Breast Cancer | Breast Cancer | phase-2 | The overall response rate was 37.3% and the clinical benefit rate was 48.8%. | Source → |
| Gemcitabine Derivative Shows Promise Against Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Gemcitabine-resistant pancreatic cancer cells identified | Pancreatic Cancer | lab-study | Pharmacological inhibition of MAOB significantly suppressed proliferation and tumor growth in both mPDAC-R and human PDAC cell lines. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.